The impact of some commonly prescribed anti-epilepsy drugs (AEDs) on female health is well documented. Yet many women continue to experience side effects such as menstrual irregularities, interactions with hormonal contraception/HRT and teratogenicity [Seizure 8 (1999) 201] through lack of awareness or opportunity to discuss problems with a health professional on a regular basis.
INTRODUCTION
The impact on female health of some anti-epilepsy drugs (AEDs) is well documented 1 . A recent UK study revealed that women aged 25-39 years undergoing treatment for epilepsy had significantly lower fertility rates than those in the general population 2 . A higher incidence of menstrual disorders has been documented among women with epilepsy 3 . Women with epilepsy may display a higher prevalence of Polycystic Ovary Syndrome (PCOS), particularly those receiving sodium valproate 4, 5 . Some commonly used anti-epilepsy drugs (phenytoin, carbamazepine, phenobarbitone, primidone, oxcarbazepine, and more recently topiramate) are enzyme inducing and interact with the contraceptive pill, reducing its effectiveness 1 thereby increasing the risk of unplanned pregnancy.
Among babies born to women with epilepsy, there is a two-to threefold increase (over the background risk of 1-2%) in congenital malformations 6 . Although other factors such as seizures and a genetic link between epilepsy and susceptibility to malformations may contribute to this increase, the greatest risk is from in utero exposure to AEDs. Major malformations associated with carbamazepine, sodium valproate and phenytoin 1 include congenital heart disease, cleft lip or palate, limb defects, genitourinary and neural tube defects 6 . There have been fewer prospective documented pregnancies on monotherapy with newer AEDs and so far clear patterns of teratogenicity have not emerged.
Evidence also suggests that there may be a link between in utero exposure to AEDs and neurodevelopmental delay, particularly with sodium valproate 7, 8 . It is therefore essential that a woman is counselled about these risks well before she conceives. Until the time that a woman is ready to conceive, it is vital that her choice of contraception is appropriate and does not fail her.
Unfortunately current epilepsy services in the UK are such that many women remain unaware of the issues or the risks. Important conversations about contraception and unplanned pregnancy and pre-conception counselling may not take place until it is too late.
To gain a more accurate picture of the level and quality of information provided for women about epilepsy and its treatment, the Ideal World survey set out to assess the information women want versus that which they were given (anecdotal experience suggested these were two different things) and the extent to which women had been made aware of their treatment options.
Market research 9 revealed that considerable apathy exists among the majority of women with epilepsy. Many are disinterested in their condition and don't want to be reminded of their epilepsy. It therefore seemed necessary to identify which aspects of epilepsy were considered most pertinent by these women; quantify the level of demand for information; and crucially find out when, how and from whom women wanted to receive information, with a view to providing it when the women were most receptive.
The 'Ideal World' survey therefore aimed to:
(a) assess current provision of treatment information to women with epilepsy at different life stages (childbearing age, pre-conception/ pregnancy, menopause);
(b) identify information needs and wants with a view to ensuring that all women with epilepsy are counselled appropriately, in a timely manner and able to make informed choices about their treatment.
METHOD
The survey content was developed in conjunction with a steering group of epilepsy specialists during 2001. Questionnaires were mailed to the female membership of Epilepsy Action aged 19+ (approximately 12 000) during the period of January 2002. In addition, the questionnaire was posted on the Epilepsy Action website and responses collected. In total, 2600 questionnaires plus 90 web responses were completed and 2000 responses were randomly selected and analysed by the Planning Shop International.
RESULTS

Demographics
Figs 1 and 2 show the numbers of women in each age group and what medication they are receiving.
What is important to women at different life stages?
The most important issues for women in the 19-44 age group who were considering having children (n = 498) are (in order of importance):
1. Risk of epilepsy/medication affecting the unborn child (87%);
2. Effect of pregnancy on seizure control (49%);
Risk of a child developing epilepsy (42%).
A full breakdown of results is shown in Fig. 3 . The key issues of importance to women in the 45+ age group are (in order of importance):
1. Epilepsy medication and osteoporosis (63%); 2. Epilepsy medication as you get older (57%); 3. Changes in seizures during the menopause (44%).
Epilepsy and contraception
Over half (53%) of women in the 19-34 age group (n = 420) are concerned that some epilepsy medications interact with the contraceptive pill making it less effective. Forty-five percent of the women (in the 19-34 age group) who indicated that they were taking an enzyme-inducing AED had not received information about oral contraception and epilepsy medication. 
Epilepsy and pregnancy
One third of women who had already had children (n = 419) were not given any information about their pregnancy and epilepsy medication and 13% were only given information after they became pregnant. Over half (54%) of the women who had been through a pregnancy had not been told that their epilepsy medication might affect their unborn child. The majority of women (75%) who have already had children had not been referred to a specialist centre or clinic in connection with their pregnancy. Only 7% of women in the 35-44 age group had been referred for specialist epilepsy care for their pregnancy. A third (32%) of women aged 19-44 who are not considering having children in the future (n = 549), said the decision was linked to their epilepsy. Overall, 43% of women who have had children have been advised about taking folic acid, with a significantly higher percentage of women in the younger age group being advised about taking this supplement. As Fig. 4 shows, 63% of women in the younger age group have been advised about taking folic acid, compared with only 34% of women in the older age group. Eleven percent of women who have had children had been told about taking Vitamin K therapy during the last month of pregnancy.
Epilepsy and menopause
A substantial minority of women (39%) over the age of 45 had not been given any information about epilepsy and its treatment in relation to the menopause/HRT. Less than a quarter (24%) of women in this age group are aware that the menopause can upset seizure control, with 28% aware that some epilepsy treatments can affect HRT. Twenty-seven percent of women are aware that some epilepsy treatments can cause osteoporosis. 
Information needs and wants
The majority of all women (84%) want to be better informed about treatment decisions while nearly half (41%) want to take a more proactive role in treatment Fig. 4 : Information given about pregnancy and epilepsy medication. The table shows that 20% were not given any information at all about pregnancy and epilepsy medication, with the percentage being higher in the 35-44 age group. Nearly a quarter of this older age group had not received information of this nature, compared with only 13% of the younger age group. This is a statistically significant difference at 99% confidence.
discussions. Forty-three percent say they want to be more informed so that they could ask their doctor to review their medication. The vast majority of women (87%), who are considering having children, would like to have more information about epilepsy treatment There is a high level of interest (72%) amongst women aged 45+ for receiving information about epilepsy and its treatment in relation to the menopause/ HRT. As many as 89% of women in this group want to receive information about epilepsy and osteoporosis.
Ideal time to receive information
In terms of the ideal time to receive information about the effect of epilepsy treatment at the different life stages, the survey confirmed a consistent preference for information before the time that it will be needed. For example, the majority of women in the survey want information about the effect of epilepsy on pregnancy and on the risk of a child developing epilepsy as they consider pregnancy. Similarly, women expressed a desire to have information on the effect of epilepsy on periods and contraception at puberty. See Table 1 for a summary.
How women wished to receive information
Overall, the majority (59%) of women would like to receive information in a written format, for example in a leaflet. Twenty-eight percent would like to receive information through conversation with a health professional. There was consistently little interest across all groups of women in receiving information via videotapes (5%), the Internet (4%) or audiocassette (2%), with only a small percentage of women stating a preference for information via these means.
DISCUSSION
Women with epilepsy are clearly not receiving important information regarding treatment, which could have profound implications for their health and the health of their unborn child. Women with epilepsy require a different approach to epilepsy treatment than men and it is therefore crucial that they receive special attention and regular treatment reviews, with referral to a specialist as appropriate, to ensure that the risk of unplanned pregnancy and birth defects are minimised.
Women clearly want to be better informed, with many wanting to take a more proactive role in their treatment and many wanting to work more in partnership with their doctors than passively accepting treatment. Women with epilepsy appear to want greater control over their treatment and their epilepsy and provision of appropriate, timely information is clearly desired by these women to help them achieve this objective.
Health professionals should encourage women to discuss aspects of their condition and possible adverse effects of treatment in a timely fashion-especially before conception-and where possible, provide the latest, most up-to-date information.
Even if pregnancy doesn't seem relevant or a priority for the patient at that moment in time, it is prudent to think ahead and discuss the matter with her so that she is primed for when the time comes. Teens are an important time to review epilepsy and adjust treatment if necessary-especially as this avoids inappropriately timed and disruptive changes later on when the patient is driving, working or living away from home or planning to have a family.
Having epilepsy should not be a limiting factor to having a child. The current situation could be improved by more women-centred clinics offering preconception counselling and treatment review as well as follow up during pregnancy and beyond. With the right information and support at the right time, women with epilepsy can make informed choices and overcome perceived barriers which often obscure the full range of options open to them. Very few specialist clinics for women with epilepsy who wish to become pregnant exist in the UK 10 , but are potentially valuable.
CONCLUSION
The survey reveals that women with epilepsy are not receiving important information regarding treatment and its possible adverse effects, which could have profound implications for their health and the health of their unborn child.
Previous studies suggest that women with epilepsy are unlikely to proactively seek a review of their treatment. To improve the current situation, all women with epilepsy of childbearing age should be offered a review, initially in general practice, to ensure that appropriate treatment changes can be made in a timely fashion. Thereafter, regular review and discussion should be encouraged to discuss treatment and stage of life issues.
